Translating that to humans, a similar higher SR-B1 expression was observed in type 2 diabetic patients, but no change in hepatic SR-B1 was observed in NASH and hypercholesterolemia patients, predicting only a minimal role of SR-B1 in NAFLD (Rein-Fischboeck et al., 2015). This evidence concerns the gene SCARB1 and metabolic dysfunction-associated steatotic liver disease.